First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

导出 OA

翻译打印收藏纠错

作者： Priska,Kaufmann ^[1] ; Marion,Ort ^[1] ; Georg,Golor ^[2] ; Rüdiger,Kornberger ^[2] ; Jasper,Dingemanse ^[1]

作者单位： Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. ^[1] Parexel International GmbH, Berlin, Germany. ^[2]

关键词 first-in-human pharmacodynamics pharmacokinetics safety and tolerability selective orexin-1 receptor antagonist

主题词投药, 口服(Administration, Oral);曲线下面积(Area Under Curve);剂量效应关系, 药物(Dose-Response Relationship, Drug);双盲法(Double-Blind Method);人类(Humans);男(雄)性(Male)

DOI 10.1111/bcp.14251

PMID 32067262

发布时间 2024-07-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

British journal of clinical pharmacology

2020年86卷7期

1377-1386页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

British journal of clinical pharmacology

相似文献

British journal of clinical pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

British journal of clinical pharmacology

相似文献

British journal of clinical pharmacology

相关期刊

检索历史清除